Financials
| Interim Results for six months ended 31 Dec 2024 | Mar. 31, 2025 |
| Half Year Trading update | Jan. 28, 2025 |
| Audited Preliminary Results 2024 | Nov. 06, 2024 |
| Trading update for the year ended 30 June 2024 | Jul. 22, 2024 |
| Interim Results for six months ended 31 Dec 2023 | Mar. 27, 2024 |
| Publication of Annual Report and Accounts 2023 | Jan. 30, 2024 |
| Annual Report and Accounts Delayed | Dec. 15, 2023 |
Proxies
| Notice of 2024 Annual General Meeting | Nov. 21, 2024 |
| Result of AGM | Mar. 08, 2024 |
| Notice of 2023 Annual General Meeting | Feb. 09, 2024 |
| Result of AGM | Feb. 07, 2023 |
| NOTICE OF 2022 ANNUAL GENERAL MEETING | Jan. 13, 2023 |
| Result of AGM | Nov. 23, 2021 |
| Result of Annual General Meeting | Dec. 08, 2020 |
Ownership Update
| New Executive Long Term Incentive Awards | Mar. 03, 2025 |
| Grant of Options | Feb. 14, 2025 |
| PDMR Dealing and Total Voting Rights | Jan. 22, 2025 |
| Director/PDMR Shareholding | Jan. 15, 2025 |
| Launch of new Company Long Term Incentive Plan | Jul. 04, 2024 |
| PDMR dealing and Total Voting Rights | Dec. 13, 2023 |
| Holding(s) in Company | Nov. 28, 2023 |
Announcements
| Allergy Therapeutics presents findings at EAACI | Jun. 13, 2025 |
| EAACI Early Career Research Award | Jun. 10, 2025 |
| Advancement to final phase of PROTECT trial | Mar. 27, 2025 |
| Presentations at 2025 AAAAI / WAO Joint Congress | Feb. 27, 2025 |
| Grass MATA MPL Phase III data published in Allergy | Feb. 17, 2025 |
| Positive Interim Data from PROTECT Trial | Dec. 04, 2024 |
| First Patient Dosed in G308 Paediatric Trial | Nov. 27, 2024 |